OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: Sunnybrook Research Institute

4 Projects | 3 Researchers | $3,967,060 Invested

2023

Sunnybrook Research Institute

Walter Swardfager, PhD

Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists as Pharmacotherapies to Prevent Dementia

  • Funding Amount: $100,000
  • Organization Type: Academic/Nonprofit
  • Program: Prevention
  • Target: Endocrinology
  • Status: Active

2019

Sunnybrook Research Institute

Krista Lanctôt, PhD

Nabilone for Agitation Blinded Intervention Trial (NAB-IT)

  • Funding Amount: $2,645,388
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Neuroinflammation
  • Status: Active

2014

Sunnybrook Research Institute

Krista Lanctôt, PhD

Safety and efficacy of nabilone in institutionalized patients with Alzheimer's Disease: a pilot study

  • Funding Amount: $229,284
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Neuroinflammation
  • Status: Closed

2012

Sunnybrook Research Institute

Sandra Black, MD, FRCP(C)

Sartans to Slow Alzheimer's Disease: A Randomized, Open-Label, Head-to-Head, Proof-of-Concept Study of Angiotensin Receptor Blockers Versus ACE Inhibitors in Hypertensive Mild-Moderate AD Patients using Ventricular Enlargement as Primary Outcome

  • Funding Amount: $992,388
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Vascular
  • Status: Closed